Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen
Brief Summary: The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease.

The secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.


Options:
A: Arm Label: S-1 and Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 & Oxaliplatin | Arm Label: Capecitabine and Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine & Oxaliplatin | Intervention Type: DRUG; Name: S-1 & Oxaliplatin; Assigned to Arm(s): S-1 and Oxaliplatin | Intervention Type: DRUG; Name: Capecitabine & Oxaliplatin; Assigned to Arm(s): Capecitabine and Oxaliplatin
B: Arm Label: Arm 1: 5-FU + RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2: 5-FU + RT + Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: fluorouracil, Drug: oxaliplatin, Radiation: radiation therapy | Arm Label: Arm 3: Capecitabine + RT; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Radiation: radiation therapy | Arm Label: Arm 4: Capecitabine + RT + Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: oxaliplatin, Radiation: radiation therapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 3: Capecitabine + RT, Arm 4: Capecitabine + RT + Oxaliplatin | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1: 5-FU + RT, Arm 2: 5-FU + RT + Oxaliplatin | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Arm 2: 5-FU + RT + Oxaliplatin, Arm 4: Capecitabine + RT + Oxaliplatin | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1: 5-FU + RT, Arm 2: 5-FU + RT + Oxaliplatin, Arm 3: Capecitabine + RT, Arm 4: Capecitabine + RT + Oxaliplatin
C: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
D: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI

Answer: D